Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 13/20 | 0.43 |
| ▸ | BCL2 | P10415 | 3/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5016786 | 0.89 | MCL1 (0.51) | MCL1BCL2POLBMAPT | |
| SCHEMBL5026984 | 0.82 | MCL1 (0.41) | MCL1BCL2FPR2 | |
| SCHEMBL5025660 | 0.81 | MCL1 (0.46) | MCL1BCL2POLBMAPT | |
| SCHEMBL5026985 | 0.80 | PPARD (0.43) | MCL1HDAC6 | |
| SCHEMBL5016769 | 0.80 | PPARD (0.44) | MCL1FPR2 | |
| SCHEMBL5027024 | 0.80 | TRPV1 (0.43) | MCL1POLBMAPT | |
| SCHEMBL5023828 | 0.80 | MCL1 (0.46) | MCL1BCL2 | |
| SCHEMBL5016882 | 0.79 | PPARD (0.45) | MCL1 | |
| SCHEMBL5023230 | 0.79 | PPARD (0.55) | MCL1 | |
| SCHEMBL5016818 | 0.78 | PPARD (0.41) | MAPTHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725546-B1 | PYRAZOLYL INDOLYL DERIVATIVES AS PPAR ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | EP | disclosed |
| US-7265149-B2 | Indolyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1725546-A1 | PYRAZOLYL INDOLYL DERIVATIVES AS PPAR ACTIVATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005085235-A1 | PYRAZOLYL INDOLYL DERIVATIVES AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-15 | — | — | WO | disclosed |
| US-20050203160-A1 | Indolyl derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203160-A1 | Indolyl derivatives | PPARD, PPARA, PPARG | MCL1 2737/4885BCL2 2207/4885FPR2 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.